SHERIDAN, WYOMING – May 8, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) today confirmed that all proposals presented at its Annual General Meeting of Shareholders (AGM) 2025 have been approved, strengthening the company’s governance structure and positioning its leadership team to execute on long-term strategic objectives in the health technology sector.
Shareholder backing of key appointments and re-appointments underscores continued investor confidence in Philips’ strategic direction. This includes the re-appointment of seasoned leaders Indra Nooyi and Chua Sock Koong to the Supervisory Board, the addition of global health tech expert Bob White, and the renewed mandate for Marnix van Ginneken as a member of the Board of Management.
Leadership Reinforcement for Strategic Execution
The AGM’s approval of board appointments represents a pivotal step in reinforcing Philips’ operational resilience and strategic agility. As the company navigates global healthcare innovation, strong governance and leadership continuity remain central to its performance and market influence.
Feike Sijbesma, Chairman of Philips’ Supervisory Board, remarked, “We are delighted to welcome Bob White to the Supervisory Board and are very pleased with the re-appointment of Indra Nooyi and Chua Sock Koong. With our highly knowledgeable and experienced members, our Supervisory Board is well-equipped to advise and support Management as they execute Philips’ strategy.”
The appointment of Bob White, a recognized figure in global health technology, is expected to bring fresh industry insights and strategic value as Philips continues driving innovation in connected care and precision health.
Board Continuity to Support Strategic Innovation
Philips’ CEO Roy Jakobs emphasized the importance of leadership continuity in advancing the company’s innovation agenda: “Philips has benefited greatly from the expertise and contributions of Indra Nooyi and Chua Sock Koong, and we are very happy with their re-appointment. Our CFO Charlotte Hanneman and I look forward to continued successful collaboration with Marnix van Ginneken who has been instrumental to Philips, as we strive to improve health and well-being of people through meaningful innovation.”
Mr. van Ginneken, re-appointed to the Board of Management effective May 8, 2025, brings strong legal and corporate governance credentials, essential to navigating evolving regulatory and global business environments.
AGM Resolutions Reflect Long-Term Value Creation
Key decisions ratified by shareholders reflect Philips’ commitment to transparency, shareholder value, and capital strategy. Among the approved resolutions were:
- Adoption of the 2024 financial statements and a dividend of EUR 0.85 per common share, payable in shares or cash.
- Positive advisory vote on the 2024 Remuneration Report.
- Discharge of Board of Management and Supervisory Board members from liability.
- Authorization for the Board of Management to issue and repurchase shares.
- Approval for cancellation of shares to manage capital efficiency.
These actions align with Philips’ focus on sustainable shareholder returns and corporate governance excellence.
Continued Focus on Operational and Market Impact
With its leadership team solidified and corporate strategies reaffirmed, Philips is positioned to capitalize on emerging opportunities in health technology, including personalized care delivery, AI-powered diagnostics, and digitally enabled patient engagement. The outcomes of the AGM signal robust support for Philips' long-term transformation and value-creation strategy.
For full AGM 2025 details and documentation, visit: https://www.philips.com